|
1）Wallace E, Fogo AB, Schulman G. Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulo-nephritis. Am J Kidney Dis. 2012; 59: 122-5
|
|
|
|
2）Iyoda M, Shibata T, Hirai Y, et al. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1486-96
|
|
|
|
|
|
3）Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011; 301: C522-9
|
|
|
|
|
|
4）Sweeney WE, Jr., von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008; 19: 1331-41
|
|
|
|
|
|
5）Bollee G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med. 2011; 17: 1242-50
|
|
|
|
|
|
6）Gilbert RE, Kelly DJ, McKay T, et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 2001; 59: 1324-32
|
|
|
|
|
|
7）Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005; 105: 2473-9
|
|
|
|
|
|
8）Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004; 18: 1332-9
|
|
|
|
|
|
9）Lee KC, Ouwehand I, Giannini AL, et al. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010; 24: 896-900
|
|
|
|
|
|
10）Gu JJ, Zhang N, He YW, et al. Defective T cell development and function in the absence of Abelson kinases. J Immunol. 2007; 179: 7334-43
|
|
|
|
|
|
11）Iyoda M, Hudkins KL, Becker-Herman S, et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol. 2009; 20: 68-77
|
|
|
|
|
|
12）Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105: 3127-32
|
|
|
|
|
|
13）Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006; 116: 2633-42
|
|
|
|
|
|
14）Iyoda M, Shibata T, Kawaguchi M, et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int. 2009; 75: 1060-70
|
|
|
|
|
|
15）Wang S, Wilkes MC, Leof EB, et al. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005; 19: 1-11
|
|
|
|
|
|
16）Savikko J, Rintala JM, Rintala SE, et al. Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol Dial Transplant. 2011; 26: 3026-32
|
|
|
|
|
|
17）Iyoda M, Shibata T, Wada Y, et al. Long-and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol Dial Transplant. 2012 Oct 8. [Epub ahead of print
|
|
|
|
|
|
18）Torres VE, Leof EB. Fibrosis, regeneration, and aging: playing chess with evolution. J Am Soc Nephrol. 2011; 22: 1393-6
|
|
|
|
|
|
19）Gafter-Gvili A, Ram R, Gafter U, et al. Renal failure associated with tyrosine kinase inhibitors-case report and review of the literature. Leuk Res. 2010; 34: 123-27
|
|
|
|
|
|
20）Ding G, Zhang A, Huang S, et al. ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol. 2007; 293: F1889-97
|
|
|
|
|
|
21）Smith JP, Pozzi A, Dhawan P, et al. Soluble HB-EGF induces epithelial-to-mesenchymal transition in inner medullary collecting duct cells by upregulating Snail-2. Am J Physiol Renal Physiol. 2009; 296: F957-65
|
|
|
|
|
|
22）Francois H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 2004; 18: 926-8
|
|
|
|
|
|
23）Richards WG, Sweeney WE, Yoder BK, et al. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest. 1998; 101: 935-9
|
|
|
|
|
|
24）Sweeney WE, Chen Y, Nakanishi K, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000; 57: 33-40
|
|
|
|
|
|
25）Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011; 80: 1271-7
|
|
|
|
|